1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsPage shows deadline of June 12, 2026 at 1 p.m. EST; stored deadline was 2026-06-01.
Impact Catalyst is sponsored by Massachusetts Life Sciences Center. Impact Catalyst aims to accelerate early-stage, high-risk translational research in underinvested life sciences areas, driving innovation and patient impact. This program supports capital projects that enable and support life sciences R&D in Massachusetts.
Get alerted about grants like this
Get emailed when new opportunities from “Massachusetts Life Sciences Center” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Massachusetts Life Sciences Center Launches Impact Catalyst Program - MLSC Massachusetts Life Sciences Center Launches Impact Catalyst Program WALTHAM, Mass.
— Today, the Massachusetts Life Sciences Center (MLSC) announced the launch of the Impact Catalyst program , a seed-stage, non-dilutive funding initiative designed to accelerate high-risk translational research for underserved patient populations in historically underinvested disease areas.
The Impact Catalyst program provides milestone-based grants of up to $250,000 to early-stage life science startups to address persistent funding gaps in hard-to-commercialize fields.
By pairing flexible, non-dilutive capital with committed private investors participating in the company’s first institutional financing round (seed round), the program aims to reduce early-stage risk, catalyze additional investment, and position promising startups for future commercialization while strengthening Massachusetts’ life sciences ecosystem.
Impact Catalyst is structured to help activate and close the financing round by directly mobilizing investor participation and strategic capital within defined life sciences sector focus areas. “The life sciences industry is a cornerstone of the Commonwealth’s economy and a key driver of long-term growth,” said Economic Development Secretary and MLSC Board Co-Chair Eric Paley .
“Through initiatives like the Impact Catalyst program, we are helping early-stage companies gain the traction they need at crucial moments, strengthening our innovation pipeline and ensuring Massachusetts remains competitive in a rapidly evolving global market. ” “Massachusetts has built its reputation by combining world-class innovation with strong networks of support,” said MLSC President and CEO Kirk Taylor, MD .
“By standing behind entrepreneurs at their earliest stages, we can help translate groundbreaking research into meaningful advancements in health care for patients with limited treatment options. ” Focus areas for the program include medical devices and diagnostics, health equity solutions, women’s health, psychiatric diseases and pain management, and microbiome and antibiotic innovation.
By directing resources to fields with significant medical and social burden, the program supports transformative solutions for underserved patient groups while building a strong pipeline of early-stage life sciences companies across the Commonwealth.
Additionally, today the MLSC launched the latest round of the Massachusetts Next Generation (MassNextGen) Initiative , continuing the Center’s commitment to supporting diverse entrepreneurs while expanding opportunity across the Massachusetts life sciences ecosystem. The application period for the Impact Catalyst program and the MassNextGen Initiative will run from March 16 through June 12, 2026 at 1 p. m.
EST. For interested companies, the MLSC offers info sessions on its initiatives that support diverse entrepreneurs and early-stage life science companies. Register today for an upcoming info session: March 24, 2026, at 11 a.
m. EST, virtual – register April 30, 2026, at 2 p. m.
EST, virtual – register May 18, 2026, at 1 p. m. EST, virtual – register Visit the MLSC’s Impact Catalyst program page to learn more.
For questions, please reach out to: impactcatalyst@masslifesciences. com . About the Massachusetts Life Sciences Center The Massachusetts Life Sciences Center (MLSC) is a quasi-public economic development and investment agency dedicated to supporting the growth and development of the life sciences in Massachusetts, home to the most verdant and productive life sciences ecosystem in the world.
Through public-private funding initiatives, the MLSC supports innovation, research and development, commercialization, and manufacturing activities in the fields of biopharma, medical device, diagnostics and digital health. Since 2008, the MLSC has strategically deployed more than $1. 1 billion in Massachusetts, through a combination of grants, loans, capital infrastructure investments, tax incentives and workforce development programs.
These investments have created thousands of jobs and propelled the development of new therapies, devices and scientific advancements that are improving patient health and well-being in Massachusetts and beyond. Announcements Featured in The Beat
According to the current listing, eligibility includes: Massachusetts-based research institutions and life sciences organizations. Confirm the full requirements in the official notice before applying.
The published deadline was June 12, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Impact Catalyst is funded by Massachusetts Life Sciences Center. Verify program details on the funder's official page before applying.
This opportunity targets applicants in Massachusetts. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
Awards slashed by half, life sciences applicants rejected at 95%, and the White House steering which fields get funded. How the GRFP went from funding the person to funding the priority.
Read articleAfter a rare gap with zero active omnibus NOFOs, NIH has reissued its SBIR/STTR parent announcements — collapsing four solicitations into two, adding a Strategic Breakthrough bridge and a Commercialization Readiness Pilot, and reopening the funnel with a September 5, 2026 receipt date. Here are the exact solicitation numbers, the new budget ceilings, what actually changed, and how a small business should sequence its submission.
Read articleAfter an authorization lapse froze new SBIR/STTR awards for five months, NIH reopens its submission window on August 5, 2026, with a first standard deadline of September 8. Phase I awards run to $323,090, Phase II to $2,153,927, with published waiver topics reaching $700,000 and $3 million — and a new Phase IIB Strategic Breakthrough lane up to $30 million. Here is how the restarted omnibus is structured, why applying early matters more than usual this cycle, and how to position a life-science startup to win.
Read article